 Catherine Jankowski
Concepts (267)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Exercise | 28 | 2023 | 1647 | 4.350 |
Why?
| | HIV Infections | 28 | 2023 | 2454 | 3.090 |
Why?
| | Body Composition | 13 | 2021 | 644 | 1.740 |
Why?
| | Neoplasms | 7 | 2023 | 2160 | 1.430 |
Why?
| | Bone Density | 8 | 2021 | 447 | 1.350 |
Why?
| | Dehydroepiandrosterone | 3 | 2018 | 51 | 1.340 |
Why?
| | Frailty | 4 | 2023 | 116 | 1.250 |
Why?
| | Quality of Life | 10 | 2023 | 2355 | 1.210 |
Why?
| | Aging | 11 | 2023 | 1675 | 1.210 |
Why?
| | Caregivers | 3 | 2023 | 707 | 1.120 |
Why?
| | Muscle, Skeletal | 7 | 2023 | 1515 | 1.010 |
Why?
| | Exercise Therapy | 6 | 2021 | 355 | 0.900 |
Why?
| | Collagen Type I | 3 | 2021 | 114 | 0.880 |
Why?
| | Ibuprofen | 2 | 2021 | 76 | 0.850 |
Why?
| | Alkaline Phosphatase | 2 | 2021 | 158 | 0.850 |
Why?
| | Art Therapy | 1 | 2022 | 16 | 0.840 |
Why?
| | Muscle Strength | 2 | 2018 | 283 | 0.810 |
Why?
| | Aged | 32 | 2023 | 19594 | 0.770 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2021 | 88 | 0.760 |
Why?
| | Mitochondria, Muscle | 1 | 2021 | 97 | 0.750 |
Why?
| | Interleukin-6 | 2 | 2021 | 685 | 0.740 |
Why?
| | HIV Long-Term Survivors | 1 | 2020 | 3 | 0.740 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2021 | 301 | 0.720 |
Why?
| | Interleukin-10 | 1 | 2021 | 304 | 0.680 |
Why?
| | Wearable Electronic Devices | 1 | 2019 | 34 | 0.670 |
Why?
| | Attitude to Health | 2 | 2019 | 410 | 0.660 |
Why?
| | Anti-HIV Agents | 7 | 2020 | 662 | 0.640 |
Why?
| | Preventive Health Services | 1 | 2020 | 133 | 0.640 |
Why?
| | Risk Reduction Behavior | 1 | 2020 | 198 | 0.640 |
Why?
| | Peptides | 3 | 2021 | 879 | 0.620 |
Why?
| | Adiposity | 3 | 2013 | 508 | 0.590 |
Why?
| | Middle Aged | 35 | 2023 | 27510 | 0.580 |
Why?
| | Perception | 1 | 2019 | 314 | 0.570 |
Why?
| | Humans | 65 | 2023 | 118251 | 0.550 |
Why?
| | Adaptation, Physiological | 3 | 2021 | 501 | 0.550 |
Why?
| | Hormone Replacement Therapy | 3 | 2018 | 80 | 0.540 |
Why?
| | Dehydroepiandrosterone Sulfate | 3 | 2013 | 44 | 0.510 |
Why?
| | Telemedicine | 1 | 2023 | 664 | 0.510 |
Why?
| | Estrogens | 4 | 2013 | 329 | 0.510 |
Why?
| | Guidelines as Topic | 2 | 2019 | 261 | 0.500 |
Why?
| | Fatigue | 5 | 2022 | 293 | 0.500 |
Why?
| | Sex Factors | 2 | 2018 | 1765 | 0.470 |
Why?
| | Heart Failure | 2 | 2023 | 1967 | 0.460 |
Why?
| | Survivors | 2 | 2014 | 411 | 0.430 |
Why?
| | Nausea | 2 | 2023 | 107 | 0.420 |
Why?
| | Inflammation | 3 | 2021 | 2545 | 0.410 |
Why?
| | Female | 39 | 2023 | 61261 | 0.390 |
Why?
| | Physical Fitness | 4 | 2017 | 179 | 0.380 |
Why?
| | Bone and Bones | 2 | 2013 | 288 | 0.380 |
Why?
| | Resistance Training | 1 | 2012 | 120 | 0.370 |
Why?
| | Acetaminophen | 1 | 2012 | 244 | 0.360 |
Why?
| | Cardiovascular Diseases | 3 | 2020 | 1795 | 0.360 |
Why?
| | Health Status | 2 | 2020 | 723 | 0.350 |
Why?
| | Male | 29 | 2023 | 57474 | 0.340 |
Why?
| | Postmenopause | 5 | 2019 | 305 | 0.340 |
Why?
| | HIV-1 | 5 | 2020 | 772 | 0.320 |
Why?
| | Sarcopenia | 2 | 2023 | 72 | 0.310 |
Why?
| | Menopause | 2 | 2021 | 266 | 0.310 |
Why?
| | Accelerometry | 2 | 2019 | 72 | 0.300 |
Why?
| | Pain | 2 | 2023 | 736 | 0.280 |
Why?
| | Glucose | 1 | 2011 | 940 | 0.280 |
Why?
| | Cross-Sectional Studies | 10 | 2023 | 4521 | 0.280 |
Why?
| | Weight Loss | 4 | 2020 | 652 | 0.280 |
Why?
| | Cancer Survivors | 2 | 2021 | 201 | 0.270 |
Why?
| | Biomarkers | 6 | 2021 | 3567 | 0.270 |
Why?
| | Qualitative Research | 4 | 2023 | 952 | 0.270 |
Why?
| | Motor Activity | 3 | 2014 | 664 | 0.260 |
Why?
| | Radioisotope Dilution Technique | 1 | 2004 | 14 | 0.250 |
Why?
| | Body Water | 1 | 2004 | 28 | 0.250 |
Why?
| | Urine | 1 | 2004 | 58 | 0.250 |
Why?
| | Deuterium | 1 | 2004 | 78 | 0.240 |
Why?
| | Absorptiometry, Photon | 4 | 2021 | 226 | 0.240 |
Why?
| | Serum | 1 | 2004 | 62 | 0.240 |
Why?
| | Contraceptives, Oral, Hormonal | 1 | 2004 | 23 | 0.240 |
Why?
| | Parents | 2 | 2022 | 1208 | 0.240 |
Why?
| | Lumbar Vertebrae | 3 | 2018 | 214 | 0.230 |
Why?
| | Saliva | 1 | 2004 | 187 | 0.230 |
Why?
| | Aged, 80 and over | 8 | 2021 | 6541 | 0.220 |
Why?
| | Femur | 2 | 2018 | 199 | 0.210 |
Why?
| | Proxy | 1 | 2022 | 22 | 0.210 |
Why?
| | Malnutrition | 1 | 2023 | 65 | 0.210 |
Why?
| | High-Intensity Interval Training | 1 | 2022 | 18 | 0.210 |
Why?
| | Voltage-Dependent Anion Channel 1 | 1 | 2021 | 9 | 0.210 |
Why?
| | Symptom Assessment | 1 | 2023 | 123 | 0.200 |
Why?
| | Adolescent | 6 | 2023 | 18364 | 0.200 |
Why?
| | Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2021 | 44 | 0.200 |
Why?
| | Citrate (si)-Synthase | 1 | 2021 | 49 | 0.200 |
Why?
| | Attitude | 1 | 2023 | 230 | 0.200 |
Why?
| | Prospective Studies | 3 | 2023 | 6443 | 0.200 |
Why?
| | Receptors, Tumor Necrosis Factor, Type II | 1 | 2021 | 36 | 0.200 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2021 | 79 | 0.190 |
Why?
| | Raloxifene Hydrochloride | 2 | 2013 | 13 | 0.180 |
Why?
| | Viral Load | 2 | 2020 | 406 | 0.180 |
Why?
| | Child, Preschool | 4 | 2023 | 9448 | 0.180 |
Why?
| | Advance Directives | 1 | 2021 | 62 | 0.180 |
Why?
| | Interviews as Topic | 2 | 2020 | 593 | 0.180 |
Why?
| | Life Expectancy | 1 | 2020 | 51 | 0.180 |
Why?
| | Cardiorespiratory Fitness | 1 | 2020 | 39 | 0.180 |
Why?
| | Protective Factors | 1 | 2020 | 90 | 0.180 |
Why?
| | Perimenopause | 1 | 2020 | 59 | 0.180 |
Why?
| | Superoxide Dismutase | 1 | 2021 | 338 | 0.170 |
Why?
| | Epigenesis, Genetic | 1 | 2023 | 536 | 0.170 |
Why?
| | DNA Methylation | 1 | 2023 | 501 | 0.170 |
Why?
| | Blood Glucose | 4 | 2013 | 1936 | 0.170 |
Why?
| | Cell Phone | 1 | 2020 | 80 | 0.170 |
Why?
| | Placebos | 2 | 2011 | 202 | 0.170 |
Why?
| | Mexican Americans | 1 | 1999 | 100 | 0.160 |
Why?
| | Disabled Persons | 2 | 2018 | 147 | 0.160 |
Why?
| | Insulin | 5 | 2013 | 2157 | 0.160 |
Why?
| | Housing | 1 | 2019 | 122 | 0.160 |
Why?
| | Advance Care Planning | 1 | 2021 | 191 | 0.150 |
Why?
| | Chronic Disease | 2 | 2021 | 1630 | 0.150 |
Why?
| | Surveys and Questionnaires | 5 | 2022 | 4684 | 0.150 |
Why?
| | Muscle Proteins | 1 | 2019 | 218 | 0.150 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2022 | 1237 | 0.150 |
Why?
| | Sleep Wake Disorders | 1 | 2020 | 238 | 0.150 |
Why?
| | Self Care | 1 | 2020 | 356 | 0.150 |
Why?
| | Women's Health | 1 | 2019 | 274 | 0.140 |
Why?
| | Obesity | 3 | 2016 | 2715 | 0.140 |
Why?
| | Risk Factors | 7 | 2020 | 8958 | 0.140 |
Why?
| | Anxiety | 1 | 2023 | 845 | 0.140 |
Why?
| | Pelvic Bones | 1 | 2018 | 125 | 0.140 |
Why?
| | Physical Therapists | 1 | 2017 | 36 | 0.140 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2021 | 1159 | 0.140 |
Why?
| | Estradiol | 1 | 2019 | 473 | 0.140 |
Why?
| | Adaptation, Psychological | 2 | 2020 | 545 | 0.130 |
Why?
| | Adult | 13 | 2022 | 31324 | 0.130 |
Why?
| | Motivation | 4 | 2022 | 502 | 0.130 |
Why?
| | Gastrointestinal Microbiome | 1 | 2021 | 538 | 0.120 |
Why?
| | Stress, Psychological | 2 | 2020 | 967 | 0.120 |
Why?
| | Sleep | 1 | 2020 | 650 | 0.120 |
Why?
| | Monitoring, Physiologic | 1 | 2016 | 268 | 0.120 |
Why?
| | Activities of Daily Living | 1 | 2017 | 353 | 0.120 |
Why?
| | Decision Making | 1 | 2021 | 806 | 0.120 |
Why?
| | Selective Estrogen Receptor Modulators | 1 | 2013 | 26 | 0.120 |
Why?
| | Physical Therapy Modalities | 1 | 2017 | 274 | 0.120 |
Why?
| | Child | 3 | 2023 | 19033 | 0.120 |
Why?
| | Microbiota | 1 | 2021 | 655 | 0.120 |
Why?
| | Developmental Disabilities | 1 | 2016 | 245 | 0.110 |
Why?
| | Frail Elderly | 3 | 2023 | 105 | 0.110 |
Why?
| | Anti-Retroviral Agents | 1 | 2015 | 207 | 0.110 |
Why?
| | Risk Assessment | 2 | 2020 | 3043 | 0.110 |
Why?
| | Double-Blind Method | 2 | 2008 | 1683 | 0.110 |
Why?
| | Depression | 2 | 2019 | 1133 | 0.110 |
Why?
| | Estrogen Replacement Therapy | 1 | 2013 | 117 | 0.110 |
Why?
| | Thigh | 2 | 2010 | 56 | 0.110 |
Why?
| | Urea Cycle Disorders, Inborn | 1 | 2012 | 22 | 0.110 |
Why?
| | Public Health | 1 | 2017 | 447 | 0.110 |
Why?
| | Prognosis | 1 | 2020 | 3424 | 0.100 |
Why?
| | Marijuana Smoking | 1 | 2015 | 220 | 0.100 |
Why?
| | Hysterectomy | 1 | 2012 | 117 | 0.100 |
Why?
| | Lipids | 2 | 2013 | 591 | 0.100 |
Why?
| | Osteoporosis, Postmenopausal | 1 | 2011 | 38 | 0.100 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2012 | 219 | 0.100 |
Why?
| | Cholesterol, HDL | 1 | 2011 | 198 | 0.100 |
Why?
| | Hip | 2 | 2011 | 46 | 0.090 |
Why?
| | Insulin-Like Growth Factor I | 2 | 2013 | 285 | 0.090 |
Why?
| | Accidental Falls | 1 | 2012 | 151 | 0.090 |
Why?
| | Osteogenesis | 1 | 2012 | 213 | 0.090 |
Why?
| | Osteoporosis | 1 | 2013 | 226 | 0.090 |
Why?
| | Subcutaneous Fat | 1 | 2010 | 78 | 0.090 |
Why?
| | Cholesterol, LDL | 1 | 2011 | 316 | 0.090 |
Why?
| | Cholesterol | 1 | 2011 | 375 | 0.090 |
Why?
| | Intra-Abdominal Fat | 1 | 2010 | 89 | 0.090 |
Why?
| | Follicle Stimulating Hormone | 2 | 2021 | 216 | 0.090 |
Why?
| | Triglycerides | 1 | 2011 | 515 | 0.090 |
Why?
| | United States | 3 | 2023 | 12488 | 0.080 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 2008 | 49 | 0.080 |
Why?
| | Geriatric Assessment | 2 | 2023 | 182 | 0.080 |
Why?
| | Cognition Disorders | 1 | 2013 | 528 | 0.080 |
Why?
| | Case-Control Studies | 2 | 2013 | 3156 | 0.080 |
Why?
| | Dyslipidemias | 1 | 2010 | 162 | 0.080 |
Why?
| | Linear Models | 2 | 2008 | 817 | 0.080 |
Why?
| | Weight Gain | 1 | 2011 | 485 | 0.080 |
Why?
| | Area Under Curve | 2 | 2010 | 293 | 0.080 |
Why?
| | Body Mass Index | 3 | 2013 | 2074 | 0.080 |
Why?
| | Diet | 2 | 2006 | 1143 | 0.080 |
Why?
| | Vascular Stiffness | 1 | 2012 | 425 | 0.080 |
Why?
| | Focus Groups | 2 | 2019 | 387 | 0.070 |
Why?
| | Transcription, Genetic | 1 | 2012 | 1322 | 0.070 |
Why?
| | Calcium, Dietary | 1 | 2006 | 55 | 0.070 |
Why?
| | Cognition | 1 | 2013 | 1026 | 0.070 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 1999 | 2159 | 0.070 |
Why?
| | Regression Analysis | 1 | 2008 | 984 | 0.070 |
Why?
| | Testosterone | 1 | 2008 | 350 | 0.060 |
Why?
| | Social Support | 2 | 2018 | 527 | 0.060 |
Why?
| | Rest | 1 | 2004 | 104 | 0.060 |
Why?
| | C-Peptide | 1 | 2004 | 139 | 0.060 |
Why?
| | Predictive Value of Tests | 1 | 2008 | 1857 | 0.060 |
Why?
| | Vitamin D | 1 | 2006 | 352 | 0.060 |
Why?
| | CD4 Lymphocyte Count | 2 | 2013 | 261 | 0.050 |
Why?
| | Glucose Tolerance Test | 1 | 2004 | 361 | 0.050 |
Why?
| | Habits | 1 | 2022 | 38 | 0.050 |
Why?
| | Insulin Resistance | 1 | 2010 | 1167 | 0.050 |
Why?
| | Survival Analysis | 2 | 2015 | 1262 | 0.050 |
Why?
| | Sex Characteristics | 1 | 2006 | 667 | 0.050 |
Why?
| | Adipose Tissue | 1 | 2005 | 595 | 0.050 |
Why?
| | Actigraphy | 1 | 2020 | 80 | 0.050 |
Why?
| | Death | 1 | 2021 | 105 | 0.050 |
Why?
| | Premenopause | 1 | 2020 | 107 | 0.040 |
Why?
| | Family | 1 | 2023 | 578 | 0.040 |
Why?
| | Energy Metabolism | 2 | 2013 | 762 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2021 | 746 | 0.040 |
Why?
| | Postprandial Period | 1 | 1999 | 96 | 0.040 |
Why?
| | Counseling | 1 | 2021 | 346 | 0.040 |
Why?
| | Social Stigma | 1 | 2020 | 87 | 0.040 |
Why?
| | Estrogen Receptor alpha | 1 | 2019 | 124 | 0.040 |
Why?
| | Affect | 1 | 2020 | 238 | 0.040 |
Why?
| | Health Services for the Aged | 1 | 2017 | 71 | 0.040 |
Why?
| | Time Factors | 3 | 2019 | 6368 | 0.030 |
Why?
| | Heart Rate | 1 | 2020 | 729 | 0.030 |
Why?
| | Liver | 1 | 2004 | 1803 | 0.030 |
Why?
| | Smartphone | 1 | 2016 | 67 | 0.030 |
Why?
| | Disabled Children | 1 | 2016 | 68 | 0.030 |
Why?
| | Human Activities | 1 | 2015 | 20 | 0.030 |
Why?
| | Professional Role | 1 | 2017 | 149 | 0.030 |
Why?
| | Tracheostomy | 1 | 2016 | 102 | 0.030 |
Why?
| | Self Efficacy | 1 | 2018 | 347 | 0.030 |
Why?
| | Pandemics | 1 | 2023 | 1338 | 0.030 |
Why?
| | Aging, Premature | 1 | 2013 | 11 | 0.030 |
Why?
| | Insulin-Like Growth Factor Binding Protein 3 | 1 | 2013 | 38 | 0.030 |
Why?
| | ADP-ribosyl Cyclase 1 | 1 | 2013 | 36 | 0.030 |
Why?
| | Body Fat Distribution | 1 | 2013 | 45 | 0.030 |
Why?
| | Amino Acids, Essential | 1 | 2012 | 12 | 0.030 |
Why?
| | Respiration, Artificial | 1 | 2016 | 543 | 0.030 |
Why?
| | Amino Acids, Branched-Chain | 1 | 2012 | 32 | 0.030 |
Why?
| | Nutritional Support | 1 | 2012 | 28 | 0.030 |
Why?
| | Dietetics | 1 | 2012 | 22 | 0.030 |
Why?
| | Ovariectomy | 1 | 2012 | 124 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 1 | 2023 | 3169 | 0.030 |
Why?
| | Muscles | 1 | 2013 | 332 | 0.030 |
Why?
| | United Kingdom | 1 | 2012 | 234 | 0.030 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2013 | 258 | 0.020 |
Why?
| | Carotid Arteries | 1 | 2012 | 184 | 0.020 |
Why?
| | Dietary Proteins | 1 | 2012 | 131 | 0.020 |
Why?
| | Bone Remodeling | 1 | 2011 | 64 | 0.020 |
Why?
| | Membrane Glycoproteins | 1 | 2013 | 443 | 0.020 |
Why?
| | Enteral Nutrition | 1 | 2012 | 172 | 0.020 |
Why?
| | Cohort Studies | 1 | 2020 | 5078 | 0.020 |
Why?
| | Weight Reduction Programs | 1 | 2011 | 93 | 0.020 |
Why?
| | Oxygen Consumption | 1 | 2012 | 585 | 0.020 |
Why?
| | Mental Health | 1 | 2015 | 566 | 0.020 |
Why?
| | Contraceptive Agents | 1 | 2010 | 56 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2019 | 2435 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2016 | 2491 | 0.020 |
Why?
| | Quality Improvement | 1 | 2017 | 962 | 0.020 |
Why?
| | Lymphocyte Activation | 1 | 2013 | 1062 | 0.020 |
Why?
| | Executive Function | 1 | 2013 | 390 | 0.020 |
Why?
| | Neuropsychological Tests | 1 | 2013 | 1027 | 0.020 |
Why?
| | Dietary Supplements | 1 | 2012 | 468 | 0.020 |
Why?
| | Ultrasonography | 1 | 2012 | 714 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2010 | 734 | 0.020 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2013 | 695 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2013 | 979 | 0.020 |
Why?
| | Colorado | 1 | 2016 | 4178 | 0.020 |
Why?
| | Patient Compliance | 1 | 2010 | 532 | 0.020 |
Why?
| | Incidence | 1 | 2012 | 2413 | 0.020 |
Why?
| | Buttocks | 1 | 2005 | 11 | 0.020 |
Why?
| | Abdomen | 1 | 2005 | 110 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2011 | 4574 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2019 | 12929 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2012 | 5230 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2010 | 2433 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2013 | 9319 | 0.010 |
Why?
| | Infant | 1 | 2012 | 8254 | 0.010 |
Why?
| | Young Adult | 1 | 2010 | 10731 | 0.010 |
Why?
| | Eating | 1 | 1995 | 366 | 0.010 |
Why?
|
|
Jankowski's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|